398 related articles for article (PubMed ID: 31484560)
21. Immunotherapy in genitourinary malignancies.
Mehta K; Patel K; Parikh RA
J Hematol Oncol; 2017 Apr; 10(1):95. PubMed ID: 28434403
[TBL] [Abstract][Full Text] [Related]
22. Evolving Role of Genomics in Genitourinary Neoplasms.
Devitt ME; Dreicer R
Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
[TBL] [Abstract][Full Text] [Related]
23. Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies.
Solanki AA; Bossi A; Efstathiou JA; Lock D; Mondini M; Ramapriyan R; Welsh J; Kang J
Eur Urol Oncol; 2019 Feb; 2(1):79-87. PubMed ID: 30929848
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.
Marciscano AE; Madan RA
Curr Treat Options Oncol; 2018 Mar; 19(3):16. PubMed ID: 29520448
[TBL] [Abstract][Full Text] [Related]
25. Landscape of Immunotherapy in Genitourinary Malignancies.
Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.
Mann SA; Lopez-Beltran A; Massari F; Pili R; Fiorentino M; Koch MO; Kaimakliotis HZ; Wang L; Scarpelli M; Ciccarese C; Moch H; Montironi R; Cheng L
Curr Drug Metab; 2017 Oct; 18(8):700-711. PubMed ID: 28524003
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for genitourinary cancer: state of the art and new perspectives.
Cattrini C; Dellepiane C; Cavo A; Buzzatti G; Tolomeo F; Messina C; Boccardo F
Anticancer Drugs; 2016 Aug; 27(7):585-99. PubMed ID: 27183027
[TBL] [Abstract][Full Text] [Related]
28. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
Benjamin DJ; Hsu R
Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
[TBL] [Abstract][Full Text] [Related]
29. Current status and future perspectives of immunotherapy against urothelial and kidney cancer.
Kobayashi T; Takeuchi A; Nishiyama H; Eto M
Jpn J Clin Oncol; 2021 Oct; 51(10):1481-1492. PubMed ID: 34389866
[TBL] [Abstract][Full Text] [Related]
30. Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy.
McGregor BA; Sonpavde GP
Eur Urol Focus; 2020 Jan; 6(1):14-16. PubMed ID: 30910391
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of avelumab for the treatment of genitourinary tumors.
Stühler V; Maas JM; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2020 Sep; 20(9):971-979. PubMed ID: 32407144
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
Jang A; Adler DM; Rauterkus GP; Bilen MA; Barata PC
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680214
[TBL] [Abstract][Full Text] [Related]
34. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA; Gheeya JS; Goswamy R; Bathala TK; Surasi DS; Gao J; Shah A; Campbell MT; Msaouel P; Goswami S; Wang J; Zurita AJ; Jonasch E; Corn PG; Aparicio AM; Siefker-Radtke AO; Sharma P; Subudhi SK; Tannir N
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326169
[TBL] [Abstract][Full Text] [Related]
35. The promise of immunotherapy in genitourinary malignancies.
Zhang T; Armstrong AJ; George DJ; Huang J
Precis Clin Med; 2018 Dec; 1(3):97-101. PubMed ID: 30687563
[TBL] [Abstract][Full Text] [Related]
36. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
37. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
38. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
39. Genitourinary cancers updates: highlights from ASCO 2023.
Qin Q; Sheffield H; Taasan SM; Wang AZ; Zhang T
J Hematol Oncol; 2023 Nov; 16(1):112. PubMed ID: 37990343
[TBL] [Abstract][Full Text] [Related]
40. Genitourinary Cancer: Updates on Treatments and Their Impact on the Kidney.
Orozco Scott P; Deshpande P; Abramson M
Semin Nephrol; 2022 Nov; 42(6):151344. PubMed ID: 37172546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]